EcoDrugPlus

Dopamine Receptor D4

Ensembl ID : ENSOKIG00005030231
Gene Symbol: DRD4
3 Cross references
180 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSOKIG00005027194
Gene Symbol: DRD4A
1 Cross references
131 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSOKIG00005030042
Gene Symbol: DRD5
3 Cross references
141 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSOKIG00005041689
Gene Symbol: LOC109902503
3 Cross references
147 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSOKIG00005050173
Gene Symbol: LOC109874662
3 Cross references
194 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOKIG00005008895
Gene Symbol: ENPP2
3 Cross references
221 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOKIG00005042065
Gene Symbol: ENPP2
3 Cross references
220 Possible Orthologues:

Egl Nine Homolog 1-Like

Ensembl ID : ENSOKIG00005047770
Gene Symbol: LOC109881113
2 Cross references
185 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOKIG00005029744
Gene Symbol: EGLN1
3 Cross references
202 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOKIG00005008238
Gene Symbol: EGLN1
3 Cross references
197 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOKIG00005041531
Gene Symbol: EGLN1
1 Cross references
151 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOKIG00005030520
Gene Symbol: EGLN1
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).